State of Alaska Department of Revenue Acquires 35,813 Shares of Progyny, Inc. (NASDAQ:PGNY)

State of Alaska Department of Revenue increased its position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 397.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 44,819 shares of the company's stock after buying an additional 35,813 shares during the period. State of Alaska Department of Revenue's holdings in Progyny were worth $751,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of PGNY. Allspring Global Investments Holdings LLC grew its holdings in Progyny by 9.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 6,260 shares of the company's stock worth $239,000 after acquiring an additional 543 shares during the last quarter. Norden Group LLC bought a new stake in Progyny during the 1st quarter worth about $566,000. Janney Montgomery Scott LLC bought a new stake in Progyny during the 1st quarter worth about $213,000. Nordea Investment Management AB grew its holdings in Progyny by 122.2% during the 1st quarter. Nordea Investment Management AB now owns 126,446 shares of the company's stock worth $4,891,000 after acquiring an additional 69,552 shares during the last quarter. Finally, Texas Permanent School Fund Corp grew its holdings in Progyny by 1.4% during the 1st quarter. Texas Permanent School Fund Corp now owns 72,971 shares of the company's stock worth $2,784,000 after acquiring an additional 974 shares during the last quarter. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Stock Up 0.9 %

Shares of Progyny stock traded up $0.15 during trading on Thursday, reaching $16.53. The company's stock had a trading volume of 1,100,427 shares, compared to its average volume of 1,369,812. The business's 50-day moving average price is $18.39 and its 200-day moving average price is $24.13. The firm has a market cap of $1.49 billion, a PE ratio of 26.00, a P/E/G ratio of 1.43 and a beta of 1.44. Progyny, Inc. has a 52 week low of $13.93 and a 52 week high of $42.08.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.17 EPS for the quarter, meeting analysts' consensus estimates of $0.17. The business had revenue of $304.09 million during the quarter, compared to the consensus estimate of $305.32 million. Progyny had a return on equity of 11.97% and a net margin of 5.54%. Progyny's revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.15 earnings per share. Equities analysts predict that Progyny, Inc. will post 0.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Canaccord Genuity Group reduced their target price on shares of Progyny from $24.00 to $18.00 and set a "hold" rating on the stock in a research note on Friday, September 20th. Leerink Partners reduced their target price on shares of Progyny from $25.00 to $21.00 and set a "market perform" rating on the stock in a research note on Thursday, September 19th. Truist Financial reduced their target price on shares of Progyny from $33.00 to $26.00 and set a "buy" rating on the stock in a research note on Thursday, September 19th. Leerink Partnrs lowered shares of Progyny from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 7th. Finally, BTIG Research lowered shares of Progyny from a "buy" rating to a "neutral" rating in a research note on Wednesday, August 7th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $27.73.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.